TAIWAN
Under review
TFDA
Taiwan Food and Drug Administration
Medical device registration
Target approval
2027 Q2
RadiOxi
RadiOxi · Fingertip physiological measurement
Fingertip sensing. Connected care.
A compact finger-clip design brings physiological measurement into everyday life. With RadiHeart AI analysis and the app, explore physiological information and long-term trends to better understand your own health patterns.
COMPACT DESIGN. FLEXIBLE CONNECTIVITY
Compact hardware. Flexible connections.
A compact device with cross-platform support and flexible connectivity. Connect to a phone, tablet or computer to fit measurement workflows across different settings.
RadiOxi specifications
- Weight
- 60 g
- Main unit dimensions (L × W × H)
- 54 × 41 × 26 mm
- Signal sampling rate
- 125 Hz
- SpO₂ range and accuracy
- 70–100%, ±2%
- SpO₂ resolution
- 1%
- Pulse rate range and accuracy
- 30–199 bpm, ±3%
- Pulse rate resolution
- 1 bpm
- Finger-clip LED wavelengths
- Red: 655 nm / Infrared: 940 nm
- Connectivity
- BLE 5.0 / USB Type-C
- Compatible platforms
- Android, iOS, Windows, macOS
- Maximum data transfer rate
- Up to 819.2 kbps
- Battery
- 3.7 V / 300 mAh rechargeable lithium-polymer battery
- Continuous use / Standby
- Over 12 hours of continuous use / Up to 180 hours on standby
- Charging time
- Approximately 2 hours to a full charge
- Charging input
- USB Type-C: 5 V ±0.25 V, maximum 1 A
- Battery protection
- Built-in overcharge, over-discharge and short-circuit protection
- Operating temperature
- 0–40 °C
- Storage / Transport temperature
- −20–60 °C
- Relative humidity
- 10–90%, non-condensing (operation, storage and transport)
- Atmospheric pressure
- 700–1060 hPa (operation, storage and transport)
- Ingress protection
- IP22
- Flammability rating
- UL94 V-1 (minimum requirement)
Based on the RadiOxi v1 specification (261021 edition). SpO₂ accuracy applies to 70–100%; 0–69% has not been validated. Actual battery life varies with usage conditions.
REGULATORY
Progress in Taiwan and Japan. Moving toward international markets.
From R&D to regulatory review, we continue to advance our plans for Taiwan and Japan.
JAPAN
Under review
PMDA
Pharmaceuticals and Medical Devices Agency
Medical device review in Japan
Target approval
2027 Q2
Both applications are under review. Q2 2027 is an estimated timeline; approval and timing remain subject to the relevant authorities’ decisions.
FAQ
RadiOxi — Frequently asked questions
Answers to common questions before and after use, helping you get more comfortable with every measurement.
CONNECT WITH RADIRAD
Partner with RadiHeart. Take innovative care further.
From professional care to personal health management, we welcome opportunities in product adoption, international distribution and research collaboration, bringing physiological sensing and AI analysis to more real-world needs.
International distributorsHealthcare and care providersInternational clinical teamsUniversities and research labs
Waveforms and app values on this page illustrate functionality. Physiological information should be interpreted by qualified professionals. Product functions and intended uses depend on the version supplied and local regulatory authorization.